Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...
Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback